Skip to product information
1 of 1

HSP Complete 15

Regular price $22.50 CAD
Regular price Retail Price: $45.00 CAD
Sale price Practitioner Price: $22.50 CAD
  • Non GMO
    Non GMO
  • Gluten Free
    Gluten Free
  • Soy Free
    Soy Free
  • Dairy Free
    Dairy Free
  • Vegan
  • Fos Free
    Fos Free
  • Made in Canada
    Made in Canada

Our Human Strain Probiotics (HSP) Complete 15 provides 7 clinically studied  human strains at a potency of 15 billion colony forming units (CFU) per vegetarian capsule. With a balance of probiotics to target the small and large intestinal flora, we have you covered. Unlike enteric coated or delayed release products, our capsules are designed to target the duodenum and exert maximal gut-brain support when taken with food.

1752 in stock

View full details

Medicinal Ingredients:

DDS-1 | 5 Billion cfu (Lactobacillus acidophilus)

BL-04 | 2 billion cfu (Bifidobacterium animalis subsp. lactis) LL-23 | 2 Billion cfu (Lactococcus lactis)

GG | 2 Billion cfu (Lactobacillus rhamnosus)

HN019 | 1.8 Billion cfu (Bifidobacterium animalis subsp. lactis) LA-14 | 1.2 Billion cfu (Lactobacillus acidophilus)

BB-06 | 1 Billion cfu (Bifidobacterium bifidum)

Non-Medicinal Ingredients: Microcrystalline cellulose, Oryza sativa (Rice) hull powder, Trehalose, hypromellose.

Digestive Benefits 

HSP Complete 15 is formulated with 2 billion CFU of Lactobacillus acidophilus DDS-1; a strain clinically shown to reduce gastrointestinal discomfort in travel and lactose intolerance. Additionally, this strain has demonstrated an ability to regulate bowel habits and stool consistency. In a double- blind placebo controlled RCT, Bifidobacterium animalis subsp. lactis HN019 was shown to significantly increase frequency of bowel movements in patients struggling with less than 3 movements per week.

Immune System Benefits

In another trial with adults 70 years of age and older, HN019 was shown to increase helper T lymphocyte and natural kill cell activity in patients with low immune response.

In a clinical trial comparing the effectiveness of various probiotic strains on immune responses, groups administered Lactobacillus acidophilus La-14 or Bifidobacterium animalis subsp. Lactis BL-04 were shown to significantly increase serum IgG, compared to controls. In a randomized, double- blind placebo controlled trial, Bifidobacterium animalis subsp. Lactis BL-04 was shown to reduce the incidence of respiratory tract infection and viral shedding after being administered during a rhinovirus infection and supplementing with the probiotic strain for an additional 28 days.

In another double blind placebo controlled trial with 465 healthy adults, Bifidobacterium animalis subsp. Lactis BL-04 (at a dose of 2 billion CFU) was shown to be more effective than placebo and a multi-strain probiotic (19% reduction vs. 27% reduction) in reducing the incidence of respiratory tract infection and improving immunity

Metabolic Benefits

Chronic medical conditions like obesity and hypertension are modifiable cardiometabolic risk factors highly predictive of hospitalization. Our HSP probiotics have been formulated to address the inflammatory biomarkers, hypercholesterolemia, and elevated BMI typically seen in people with reduced immune function. In a randomized double-blind placebo controlled trial with 32 overweight and obese women, our HSP strains were shown to be significantly correlated with BMI, weight, fat mass, lean mass, conicity index, protein intake, monounsaturated fat intake, glycated hemoglobin, TNF-α, and IL6/IL10. The bifidobacteria HSP strains have also demonstrated specific cholesterol absorption properties, leading to decreases in serum total cholesterol and LDL-C.

Heavily Clinically Researched Strains 

Lactobacillus rhamnosus GG is among the world’s most heavily studied probiotic strains, and it is an integral part of our HSP Complete formula. With a dose of 2 billion CFU, your digestive, cognitive, and immune health are covered.

Supplementation of rhamnosus GG has been  clinically shown to reduce the risk of upper respiratory tract infections, rhinovirus-induced symptoms, acute otitis media, and antibiotic use in populations dealing with viral respiratory infections.

In trials with hospitalized children in both India and Poland, supplementation with rhamnosus GG significantly reduced hospital stay, along with frequency & duration of diarrhea–and ensuing IV therapy–requirements. In rotavirus-associated diarrhea, rhamnosus GG supplementation reduced the duration of symptoms, improved gastrointestinal function, and increased IgG.

In patients with Ulcerative Colitis, rhamnosus GG was shown to be as effective as mesalazine with respect to relapse rate after 6 months of supplementation The probiotic had a better adverse event profile, and was more effective than the drug in promoting “relapse-free time”.

In a randomized placebo controlled trial tracking 6 month old infants to 13 years of age, use of lactobacillus rhamnosus GG resulted in significant risk reduction of ADHD and Asperger’s syndrome.

In two separate clinical trials, rhamnosus GG supplementation starting in the second trimester of pregnancy reduced the severity of maternal allergic disease. During pregnancy and breastfeeding up to the first 2 years of an infant’s life, a study on maternal rhamnosus GG supplementation demonstrated a reduced risk of atopic dermatitis.  Extending the benefits to immune and skin health even further, rhamnosus GG supplementation has also been shown to reduce the risk of a child developing atopic dermatitis (eczema), compared to placebo, when taken consistently in the first 7 years of life.

  • Bordoni A, Amaretti A, Leonardi A, et al. Cholesterol-lowering probiotics: in vitro selection and in vivo testing of bifidobacteria. Appl Microbiol Biotechnol. 2013;97(18):8273-8281. doi:10.1007/ s00253-013-5088-2
  • Davidson, Lisa E. et al. “Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influen- za Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial.” European journal of clinical nutrition 65 (2011): 501 - 507.
  • Wang B, Hylwka T, Smieja M, Surrette M, Bowdish DME, Loeb M. Probiotics to Prevent Respi- ratory Infections in Nursing Homes: A Pilot Randomized Controlled Trial. J Am Geriatr Soc. 2018;66(7):1346-1352. doi:10.1111/jgs.15396.
  • Liu, S., Hu, P., Du, X. et al. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: A Meta-analysis of Randomized, Placebo-controlled Trials . Indian Pediatr 50, 377–381 (2013)
  • Basu S, Paul DK, Ganguly S, Chatterjee M, Chandra PK. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized con- trolled trial. J Clin Gastroenterol. 2009 Mar;43(3):208-13. doi: 10.1097/MCG.0b013e31815a5780. PMID: 18813028.
  • Czerwionka-Szaflarska M, Murawska S, Swincow G. Evaluation of influence of oral treatment with probiotic and/or oral rehydration solution in the course of acute diarrhea in children. Gastroenterology Review/Przegląd Gastroenterologiczny. 2009;4(3):166-172.
  • Sindhu KN, Sowmyanarayanan TV, Paul A, et al. Immune response and intestinal perme- ability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2014;58(8):1107-1115. doi:10.1093/cid/ciu065.
  • Pieścik-Lech, Małgorzata et al. “Lactobacillus GG (LGG) and smectite versus LGG alone for acute gastroenteritis: a double-blind, randomized controlled trial.” European Journal of Pediatrics 172 (2012): 247 - 253.
  • Zocco, M A et al. “Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.” Alimentary pharmacology & therapeutics vol. 23,11 (2006): 1567-74. doi:10.1111/j.1365- 2036.2006.02927.x.
  • Pärtty A, Kalliomäki M, Wacklin P, Salminen S, Isolauri E. A possible link between early probi- otic intervention and the risk of neuropsychiatric disorders later in childhood: a random- ized trial. Pediatr Res. 2015 Jun;77(6):823-8. doi: 10.1038/pr.2015.51. Epub 2015 Mar 11. PMID: 25760553.

  • Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bi- fidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. doi:10.1080/1949 0976.2017.1412908.
  • Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001;74(6):833-839. doi:10.1093/ajcn/74.6.833.
  • Paineau D, Carcano D, Leyer G, et al. Effects of seven potential probiotic strains on specific im- mune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53(1):107-113. doi:10.1111/j.1574-695X.2008.00413.x
  • Turner et al., (2017) ‘Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomized controlled trial’ Beneficial Microbes, 8(2): 207-215.
  • West NP et al., (2014), ‘Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy, physically active individuals’, Clinical Nutrition, 33(4):581-7.
  • Simon M, Pizzorno J, Katzinger J. Modifiable Risk Factors for SARS-CoV-2. Integr Med (Encini- tas). 2021;20(5):8-14.
  • Gomes AC, Hoffmann C, Mota JF. Gut microbiota is associated with adiposity markers and probiotics may impact specific genera. Eur J Nutr. 2020;59(4):1751-1762. doi:10.1007/s00394- 019-02034-0